medigraphic.com
ISSN 0326-3428 (Impreso)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2022, Número 1

<< Anterior Siguiente >>

Rev Nefrol Dial Traspl 2022; 42 (1)


HLA-G y su función en trasplantes de órganos sólidos

Becerra RJA

Idioma: Español
Referencias bibliográficas: 49
Paginas: 83-97
Archivo PDF: 605.52 Kb.


RESUMEN

El trasplante de órganos sólidos se ha considerado el fin último para algunas enfermedades crónicas en estadio terminal, sin embargo, las incompatibilidades del HLA entre el donante y el receptor pueden permitir que la alorespuesta se convierta en nociva para el órgano trasplantado, respuesta que puede ser tanto innata como adaptativa. Se ha identificado el HLA-G como una molécula natural inductora de tolerancia (28) principalmente en el embarazo y se considera una molécula del HLA clase I no clásico, sin embargo, comparte algunas características estructurales con el HLA clásico. Los genes HLA-G se caracterizan por tener un limitado polimorfismo y una distribución celular y tisular restringida al trofoblasto fetal y células del epitelio tímico entre otras.La búsqueda persistente de la tolerancia en los trasplantes de órganos ha permitido un estudio específico del HLA-G, como posibilidad terapéutica para aumentar la sobrevida tanto de los injertos como de los pacientes trasplantados, es por tal motivo que se realiza una revisión en dicha molécula para estimular la investigación y entendimiento de sus funciones.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Carosella ED, Rouas-Freiss N, Tronik-Le RouxD, Moreau P, LeMaoult J. HLA-G: An ImmuneCheckpoint Molecule. Adv Immunol. 2015;127:33-144. doi: 10.1016/bs.ai.2015.04.001.

  2. Hviid TV. HLA-G in human reproduction: aspects ofgenetics, function and pregnancy complications. HumReprod Update. 2006;12(3):209-32. doi: 10.1093/humupd/dmi048.

  3. Abbas AK, Lichtman AH, Pillai S. Cellular andmolecular immunology. 8th ed. Philadelphia, PA:Elsevier/Saunders, 2015. 535 p.

  4. Moreau P, Flajollet S, Carosella ED. Non-classicaltranscriptional regulation of HLA-G: an update. J CellMol Med. 2009;13(9B):2973-89. doi: 10.1111/j.1582-4934.2009.00800.x.

  5. Mouillot G, Marcou C, Zidi I, Guillard C,Sangrouber D, Carosella ED, et al. Hypoxiamodulates HLA-G gene expression in tumor cells.Hum Immunol. 2007;68(4):277-85. doi: 10.1016/j.humimm.2006.10.016.

  6. Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, etal. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancerscreening. Tumour Biol. 2015;36(4):3035-42. doi:10.1007/s13277-014-2938-1.

  7. Castelli EC, Ramalho J, Porto IO, Lima TH, Felício LP,Sabbagh A, et al. Insights into HLA-G genetics providedby worldwide haplotype diversity. Front Immunol.2014;5:476. doi: 10.3389/fimmu.2014.00476.

  8. Jassem RM, Shani WS, Loisel DA, Sharief M,Billstrand C, Ober C. HLA-G polymorphismsand soluble HLA-G protein levels in women withrecurrent pregnancy loss from Basrah province in Iraq.Hum Immunol. 2012;73(8):811-7. doi: 10.1016/j.humimm.2012.05.009.

  9. Donadi EA, Castelli EC, Arnaiz-Villena A, Roger M,Rey D, Moreau P. Implications of the polymorphismof HLA-G on its function, regulation, evolution anddisease association. Cell Mol Life Sci. 2011;68(3):369-95. doi: 10.1007/s00018-010-0580-7.

  10. Castro MJ, Morales P, Martínez-Laso J, AllendeL, Rojo-Amigo R, González-Hevilla M, et al.Evolution of MHC-G in humans and primatesbased on three new 3’UT polymorphisms. HumImmunol. 2000;61(11):1157-63. doi: 10.1016/s0198-8859(00)00188-9.

  11. Le Page ME, Goodridge JP, John E, ChristiansenFT, Witt CS. Killer Ig-like receptor 2DL4 does notmediate NK cell IFN-γ responses to soluble HLA-Gpreparations. J Immunol. 2014;192(2):732-40. doi:10.4049/jimmunol.1301748.

  12. Bahri R, Hirsch F, Josse A, Rouas-Freiss N, BidereN, Vasquez A, et al. Soluble HLA-G inhibits cell cycleprogression in human alloreactive T lymphocytes.J Immunol. 2006;176(3):1331-9. doi: 10.4049/jimmunol.176.3.1331.

  13. Naji A, Menier C, Morandi F, Agaugué S, Maki G,Ferretti E, et al. Binding of HLA-G to ITIM-bearingIg-like transcript 2 receptor suppresses B cell responses.J Immunol. 2014;192(4):1536-46. doi: 10.4049/jimmunol.1300438.

  14. Apps R, Gardner L, Sharkey AM, Holmes N, MoffettA. A homodimeric complex of HLA-G on normaltrophoblast cells modulates antigen-presenting cellsvia LILRB1. Eur J Immunol. 2007;37(7):1924-37. doi:10.1002/eji.200737089.

  15. 15.) Liang S, Baibakov B, Horuzsko A. HLA-G inhibits thefunctions of murine dendritic cells via the PIR-B immuneinhibitory receptor. Eur J Immunol. 2002;32(9):2418-26. doi: 10.1002/1521-4141(200209)32:9<2418::AIDIMMU2418>3.0.CO;2-L.

  16. LeMaoult J, Krawice-Radanne I, Dausset J, CarosellaED. HLA-G1-expressing antigen-presenting cellsinduce immunosuppressive CD4+ T cells. Proc NatlAcad Sci U S A. 2004;101(18):7064-9. doi: 10.1073/pnas.0401922101.

  17. Le Rond S, Azéma C, Krawice-Radanne I, DurrbachA, Guettier C, Carosella ED, et al. Evidence to supportthe role of HLA-G5 in allograft acceptance throughinduction of immunosuppressive/ regulatory T cells.J Immunol. 2006;176(5):3266-76. doi: 10.4049/jimmunol.176.5.3266.

  18. Amodio G, Comi M, Tomasoni D, Gianolini ME,Rizzo R, LeMaoult J, et al. HLA-G expression levelsinfluence the tolerogenic activity of human DC-10.Haematologica. 2015;100(4):548-57. doi: 10.3324/haematol.2014.113803.

  19. Brown R, Kabani K, Favaloro J, Yang S, HoPJ, Gibson J, et al. CD86+ or HLA-G+ can betransferred via trogocytosis from myeloma cellsto T cells and are associated with poor prognosis.Blood. 2012;120(10):2055-63. doi: 10.1182/blood-2012-03-416792.

  20. Lila N, Carpentier A, Amrein C, Khalil-Daher I, DaussetJ, Carosella ED. Implication of HLA-G molecule inheart-graft acceptance. Lancet. 2000;355(9221):2138.doi: 10.1016/S0140-6736(00)02386-2.

  21. Bahri R, Naji A, Menier C, Charpentier B, CarosellaED, Rouas-Freiss N, et al. Dendritic cells secrete theimmunosuppressive HLA-G molecule upon CTLA4-Ig treatment: implication in human renal transplantacceptance. J Immunol. 2009;183(11):7054-62. doi:10.4049/jimmunol.0803054.

  22. Sheshgiri R, Gustafsson F, Sheedy J, Rao V, RossHJ, Delgado DH. Everolimus but not mycophenolatemofetil therapy is associated with soluble HLA-Gexpression in heart transplant patients. J Heart LungTransplant. 2009;28(11):1193-7. doi: 10.1016/j.healun.2009.07.009.

  23. Misra MK, Pandey SK, Kapoor R, Sharma RK,Kapoor R, Prakash S, et al. HLA-G gene expressioninfluenced at allelic level in association with endstage renal disease and acute allograft rejection.Hum Immunol. 2014;75(8):833-9. doi: 10.1016/j.humimm.2014.06.005.

  24. Rebmann V, da Silva Nardi F, Wagner B, Horn PA.HLA-G as a tolerogenic molecule in transplantationand pregnancy. J Immunol Res. 2014;2014:297073.doi: 10.1155/2014/297073.

  25. Capittini C, Bergamaschi P, Sachetto S, Truglio M,Viola M, Marchesi A, et al. The plasma levels of solubleHLA-G molecules correlate directly with CD34+ cellconcentration and HLA-G 14bp insertion/insertionpolymorphism in cord blood donors. Blood Transfus.2014;12(Suppl 1):s361-6. doi: 10.2450/2012.0144-12.

  26. Jacqueline Macedo Pereira J. Molécula HLA-Gy su importancia en la inmunorregulación de launidad feto-materna: aplicaciones en inmunoterapiacelular [Tesis]. Universidad Complutense de Madrid,2015. Disponible en: (consulta: ).

  27. Cervera I, Herraiz MA, Peñaloza J, Barbolla ML,Jurado ML, Macedo J, et al. Human leukocyteantigen-G allele polymorphisms have evolved followingthree different evolutionary lineages based on intronsequences. Hum Immunol. 2010;71(11):1109-15. doi:10.1016/j.humimm.2010.07.003.

  28. Rincón V, Manrique E. HLA-G: Su importanciainmunológica. Nova; 2006:4(5):91-9. doi:10.22490/24629448.352.

  29. Le Gal FA, Riteau B, Sedlik C, Khalil-Daher I, MenierC, Dausset J, et al. HLA-G-mediated inhibition ofantigen-specific cytotoxic T lymphocytes. Int Immunol.1999;11(8):1351-6. doi: 10.1093/intimm/11.8.1351.

  30. LeMaoult J, Daouya M, Wu J, Loustau M,Horuzsko A, Carosella ED. Synthetic HLA-G proteinsfor therapeutic use in transplantation. FASEB J.2013;27(9):3643-51. doi: 10.1096/fj.13-228247.

  31. Rouas-Freiss N, LeMaoult J, Moreau P, Dausset J,Carosella ED. HLA-G in transplantation: a relevantmolecule for inhibition of graft rejection? Am JTransplant. 2003;3(1):11-6. doi: 10.1034/j.1600-6143.2003.30103.x.

  32. Ferreira LMR, Meissner TB, Tilburgs T, StromingerJL. HLA-G: at the interface of maternal-fetal tolerance.Trends Immunol. 2017;38(4):272-86. doi: 10.1016/j.it.2017.01.009.

  33. Ajith A, Portik-Dobos V, Horuzsko DD, Kapoor R,Mulloy LL, et al. HLA-G and humanized mouse modelsas a novel therapeutic approach in transplantation.Hum Immunol. 2020;81(4):178-85. doi: 10.1016/j.humimm.2020.02.006.

  34. Baştürk B, Karakayali F, Emiroğlu R, Sözer O,Haberal A, Bal D, et al. Human leukocyte antigen-G, anew parameter in the follow-up of liver transplantation.Transplant Proc. 2006;38(2):571-4. doi: 10.1016/j.transproceed.2005.12.108.

  35. Ezeakile M, Portik-Dobos V, Wu J, Horuzsko DD,Kapoor R, Jagadeesan M, et al. HLA-G dimers in theprolongation of kidney allograft survival. J ImmunolRes. 2014;2014:153981. doi: 10.1155/2014/153981.

  36. Shrestha B, Haylor J, Raftery A. Historical perspectivesin kidney transplantation: an updated review. ProgTransplant. 2015;25(1):64-9, 76. doi: 10.7182/pit2015789.

  37. Sass DA, Doyle AM. Liver and kidney transplantation:a half-century historical perspective. Med ClinNorth Am. 2016;100(3):435-48. doi: 10.1016/j.mcna.2015.12.001.

  38. Becker LE, Süsal C, Morath C. Kidney transplantationacross HLA and ABO antibody barriers. Curr OpinOrgan Transplant. 2013;18(4):445-54. doi: 10.1097/MOT.0b013e3283636c20.

  39. Billingham R, Brent L, Medawar PB. Actively acquiredtolerance of foreign cells. Nature. 1953;172(4379):603-6. doi: 10.1038/172603a0.

  40. Thorsby E. A short history of HLA. TissueAntigens. 2009;74(2):101-16. doi: 10.1111/j.1399-0039.2009.01291.x.

  41. Kissmeyer-Nielsen F, Olsen S, Petersen VP, FjeldborgO. Hyperacute rejection of kidney allografts, associatedwith pre-existing humoral antibodies against donorcells. Lancet. 1966;2(7465):662-5. doi: 10.1016/s0140-6736(66)92829-7.

  42. Lafferty KJ, Cunningham AJ. A new analysis ofallogeneic interactions. Aust J Exp Biol Med Sci.1975;53(1):27-42. doi: 10.1038/icb.1975.3.

  43. Zinkernagel RM, Doherty PC. Immunologicalsurveillance against altered self componentsby sensitised T lymphocytes in lymphocyticchoriomeningitis. Nature. 1974;251(5475):547-8. doi:10.1038/251547a0.

  44. Rowntree LC, Nguyen TH, Gras S, Kotsimbos TC,Mifsud NA. Deciphering the clinical relevance of allohumanleukocyte antigen cross-reactivity in mediatingalloimmunity following transplantation. Curr OpinOrgan Transplant. 2016;21(1):29-39. doi: 10.1097/MOT.0000000000000264.

  45. Adams AB, Williams MA, Jones TR, ShirasugiN, Durham MM, Kaech SM, et al. Heterologousimmunity provides a potent barrier to transplantationtolerance. J Clin Invest. 2003;111(12):1887-95. doi:10.1172/JCI17477.

  46. Arnaiz-Villena A, Juarez I, Suarez-Trujillo F,López-Nares A, Vaquero C, Palacio-Gruber J, et al.HLA-G: function, polymorphisms and pathology. IntJ Immunogenet. 2021;48(2):172-192. doi: 10.1111/iji.12513.

  47. Pirri A, Contieri FC, Benvenutti R, Bicalho MdaG. A study of HLA-G polymorphism and linkagedisequilibrium in renal transplant patients and theirdonors. Transpl Immunol. 2009;20(3):143-9. doi:10.1016/j.trim.2008.09.012.

  48. Durmanova V, Bandzuchova H, Zilinska Z,Tirpakova J, Kuba D, Buc M, et al. Associationof HLA-G polymorphisms in the 3’UTR regionand soluble HLA-G with kidney graft outcome.Immunol Invest. 2019;48(6):644-58. doi:10.1080/08820139.2019.1610888.

  49. Janssen M, Thaiss F, Nashan B, Koch M, ThudeH. Donor derived HLA-G polymorphisms havea significant impact on acute rejection in kidneytransplantation. Hum Immunol. 2019;80(3):176-83.doi: 10.1016/j.humimm.2018.12.011.




2020     |     www.medigraphic.com